Beyond GLP ‐1

作者
Zachary T. Bloomgarden
出处
期刊:Journal of Diabetes [Wiley]
卷期号:18 (2): e70204-e70204
标识
DOI:10.1111/1753-0407.70204
摘要

The prevalence of obesity in the United States increased from 19.3% of the adult population in 1990 to 42.5% in 2022, with a forecasted increase to 46.9% in 2035 [1]; globally the trends appear similar [2]. The glucagon-like peptide-1 receptor agonists (GLP1-RAs) have shown remarkable success in treating overweight and obesity, with 12% of adults in the United States said to have at least temporarily received one of these agents [3]. However, a number of issues should be considered in GLP-1RA use. Not all treated individuals have the desired degree of weight loss; this is particularly an issue for people with type 2 diabetes, for whom the degree of weight loss is less than that among people not having diabetes [4]. Gastrointestinal intolerance prevents a sizable number of people from using these agents or necessitates their use in lower doses. We have reviewed the question as to whether weight loss-associated decrease in muscle mass may lead to clinical sarcopenia, in turn associated with frailty and susceptibility to a variety of adverse consequences [5]. It is likely that these considerations are relevant to important subsets of treated individuals as we further extend weight control agents to address more chronic illnesses. The development of novel approaches to attain weight loss, with greater gastrointestinal tolerability, and without reduction in muscle mass should then be seen as a priority. The approaches being evaluated span a variety of different mechanisms. Their use will almost certainly be developed in conjunction with GLP-1RAs, potentially allowing more tolerable dosing and a greater degree of weight loss in. Over the coming issues of the Journal of Diabetes, we will review some potential adjunctive agents that may find efficacy in combination with the GLP-1RA in an effort to stimulate discussion of these approaches (Figure 1). We look forward to contributions to the Journal addressing these approaches. The author has nothing to report. The author declares no conflicts of interest.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
NexusExplorer的应助被Vincent采纳,获得10
刚刚
刚刚
yu完成签到 ,获得积分10
1秒前
7秒前
爆米花的应助被Vincent采纳,获得10
9秒前
13秒前
HAPPY完成签到,获得积分10
14秒前
桐桐的应助被Vincent采纳,获得10
15秒前
keleboys完成签到 ,获得积分10
17秒前
HMZ完成签到 ,获得积分10
19秒前
20秒前
HU完成签到 ,获得积分10
22秒前
23秒前
27秒前
小尾巴完成签到 ,获得积分10
30秒前
章鱼行者完成签到,获得积分10
30秒前
鲁文杰发布了新的文献求助10
31秒前
Maestro_S的应助被Vincent采纳,获得10
33秒前
34秒前
万能图书馆的应助被Vincent采纳,获得10
40秒前
40秒前
水静完成签到,获得积分10
41秒前
川川完成签到 ,获得积分10
45秒前
46秒前
科研通AI6.4的应助被Vincent采纳,获得10
46秒前
47秒前
标致访旋完成签到,获得积分10
48秒前
烂漫墨镜完成签到 ,获得积分10
51秒前
20230054发布了新的文献求助10
53秒前
53秒前
隐形曼青的应助被Vincent采纳,获得10
55秒前
鲁文杰完成签到,获得积分10
58秒前
58秒前
整齐百褶裙完成签到 ,获得积分10
1分钟前
Changhiwi完成签到 ,获得积分10
1分钟前
李健的小迷弟的应助被Vincent采纳,获得10
1分钟前
1分钟前
彳系禾完成签到 ,获得积分10
1分钟前
Jzhaoc580完成签到 ,获得积分10
1分钟前
冷艳凡灵完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190366
求助须知:如何正确求助?哪些是违规求助? 9577437
关于积分的说明 21852521
捐赠科研通 7788988
什么是DOI,文献DOI怎么找? 3436315
关于科研通互助平台的介绍 2560144
邀请新用户注册赠送积分活动 2482995